PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 28, 2026Archives of Oral Biology0 citationsOpen Access

DDX24 exacerbates inflammation-induced immunosuppression in oral squamous cell carcinoma progression through IL-17 signaling pathway

View Full Paper
WLWei LiuHCHao CuiBLBowen Li

Key Points

  • This study aims to elucidate the regulatory mechanism of DDX24 in oral squamous cell carcinoma (OSCC) and its impact on inflammation and immune response.
  • Analyzed DDX24 expression in OSCC and normal tissues using bioinformatics.
  • Knocked down DDX24 in CAL27 cells with siRNA and assessed biological functions via CCK8, wound healing, and transwell assays.
  • Developed an OSCC mouse xenograft model to evaluate DDX24 knockdown effects on tumor growth and the immune microenvironment.
  • DDX24 expression correlates with poor prognosis and reduced survival in OSCC patients.
  • DDX24 knockdown significantly inhibits OSCC proliferation both in vitro and in vivo.
  • RNA sequencing shows that DDX24 knockdown markedly attenuates activity within the IL-17 signaling pathway.

Abstract

Objective DEAD-box ATPase 24 (DDX24) plays crucial roles in the development and progression of cancers, including oral squamous cell carcinoma (OSCC). However, its regulatory mechanism and functional role remain unclear. This study aims to investigate the regulatory mechanism of DDX24 in OSCC. Design DDX24 expression and its clinical significance in OSCC and normal tissues were analyzed through bioinformatics analysis. Small interfering RNA (siRNA) was utilized to knockdown (KD) DDX24 expression in CAL27 cells, and assessed biological functions using CCK8, wound healing assays and transwell assay. RNA sequencing was further employed to elucidate the molecular mechanisms underlying DDX24 promotes malignant phenotypes in OSCC. A stable DDX24 knockdown cell line was established, and inflammatory factors expression were quantified by quantitative PCR. An OSCC mouse xenograft model was developed to evaluate the effects of DDX24 knockdown on tumor growth and the immune microenvironment in vivo. Clinical validation pinpoints the importance of the DDX24/ Interleukin-17(IL-17) axis in OSCC using tissue microarray analysis. Results DDX24 expression correlates with poor prognosis and reduced survival in OSCC patients. DDX24 KD inhibits OSCC proliferation in vitro and in vivo . RNA sequencing analysis revealed that DDX24 KD markedly attenuated the activity of the IL-17 signaling pathway. Mechanistically, DDX24 facilitates the malignant progression of OSCC by regulating inflammatory factor secretion via the IL-17 signaling pathway, thereby exacerbating tumor-associated inflammation and promoting an immunosuppressive tumor microenvironment. Conclusion This study identifies the DDX24/IL-17 axis as a key promoter of OSCC progression and provides a theoretical basis for developing targeted therapies.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Liu et al. (2026) studied this question.

synapsesocial.com/papers/6a17db293fad632b0f9d7f4dhttps://doi.org/10.1016/j.archoralbio.2026.106639
Ask AI
Helpful
Bookmark
Share
View Full Paper